Mass General Brigham Ventures

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Tuesday Health is a healthcare company that focuses on providing supportive care to individuals with serious illnesses. It aims to ease symptoms and reduce stress, enabling patients to spend more time at home with their loved ones. The company specializes in personalized, innovative care plans and delivers compassionate, supportive care through a value-based palliative care model.

InStride Health is an outpatient care platform focused on delivering evidence-based treatment for pediatric anxiety and obsessive-compulsive disorder (OCD). The company offers a tailored virtual care journey that includes individual and group therapy, coaching, and medication management. This comprehensive approach is facilitated by a coordinated team of experienced psychiatrists, therapists, and coaches, ensuring that children and teenagers receive effective and accessible care. InStride Health aims to engage young patients and their families in their treatment, making mental health support both affordable and effective.

Nocion Therapeutics is a biopharmaceutical company developing novel therapies called 'nocions' that selectively target actively firing nociceptors to provide relief for serious conditions such as cough, itch, pain, and inflammation.

Abridge is a healthcare technology company that uses generative AI to automate transcription and summarization of medical conversations, turning patient-clinician discussions into structured clinical notes in real time and integrating with electronic health record systems. The platform reduces manual note-taking, improves documentation accuracy, and enhances patient understanding by providing clear, understandable summaries. It supports clinicians across clinical, nursing, and revenue cycle workflows while prioritizing data security and patient privacy and complying with healthcare regulations. The system offers an audio-based recording and summarization approach with a customizable interface to tailor notes to patient needs.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Violet Therapeutics is a pre-clinical stage biotechnology company focused on drug discovery for central nervous system diseases. The company utilizes innovative platforms that identify, map, and analyze cellular connectomes through barcoded viral tracing, offering insights into cell-cell interactions at a single-cell level. This approach aims to facilitate advancements in the understanding and treatment of neuroinflammation. Co-founded by Mass General Brigham Ventures and researchers from Brigham & Women’s Hospital, Violet Therapeutics is committed to exploring novel therapeutic targets to develop effective treatments for complex neurological conditions.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

CodaMetrix develops an AI-powered platform for healthcare revenue cycle management. Its platform uses machine learning, deep learning, and natural language processing to autonomously translate clinical notes into billing and diagnostic codes, reducing human workload while maintaining coding accuracy.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to eliminate dependency on donor or patient cells for blood stem cell transplants, leveraging a platform technology that generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free, providing patients with rapid and broad access to durable therapies.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

FireCyte Therapeutics is developing treatments targeting microglia and neuroinflammation for progressive neurodegenerative eye diseases such as glaucoma and age-related macular degeneration.

InStride Health is an outpatient care platform focused on delivering evidence-based treatment for pediatric anxiety and obsessive-compulsive disorder (OCD). The company offers a tailored virtual care journey that includes individual and group therapy, coaching, and medication management. This comprehensive approach is facilitated by a coordinated team of experienced psychiatrists, therapists, and coaches, ensuring that children and teenagers receive effective and accessible care. InStride Health aims to engage young patients and their families in their treatment, making mental health support both affordable and effective.

Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

Carta Healthcare provides a software-as-a-service platform that maps the patient journey through hospitals by integrating data from existing information systems. The platform identifies potential bottlenecks weeks in advance and issues alerts about bed shortages and cancellations. It enables hospitals to personalize care by analyzing past patient journeys and using machine learning to predict what the current patient will need and what to expect during treatment. Its clinical data abstraction capabilities automate extraction and processing to improve efficiency, accuracy, and compliance. The solution supports hospitals and research organizations in optimizing patient care, resource allocation, and operational decisions. Founded in 2016 and based in San Mateo, California, Carta Healthcare focuses on turning disparate clinical data into actionable insights to improve care delivery.

SwanBio Therapeutics is a biotechnology company dedicated to developing innovative therapies for neurological diseases. The firm specializes in genetically defined treatments aimed at addressing various neurological disorders, including adrenomyeloneuropathy (AMN). By focusing on the development and commercialization of its therapeutic technology, SwanBio seeks to provide effective solutions that can significantly improve clinical outcomes for patients affected by such conditions.

DexCare is a Seattle-based company founded in 2021 that specializes in providing a platform-as-a-service solution for managing health system capacity and demand across various lines of care. The company's platform aims to transform traditional patient-to-provider relationships into scalable digital experiences, thereby increasing revenue from new patients while reducing acquisition costs. By optimizing access to healthcare services, DexCare helps healthcare institutions generate new patients, enhance satisfaction, achieve cost savings, and ensure that patients receive timely and effective care.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to eliminate dependency on donor or patient cells for blood stem cell transplants, leveraging a platform technology that generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free, providing patients with rapid and broad access to durable therapies.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Carta Healthcare provides a software-as-a-service platform that maps the patient journey through hospitals by integrating data from existing information systems. The platform identifies potential bottlenecks weeks in advance and issues alerts about bed shortages and cancellations. It enables hospitals to personalize care by analyzing past patient journeys and using machine learning to predict what the current patient will need and what to expect during treatment. Its clinical data abstraction capabilities automate extraction and processing to improve efficiency, accuracy, and compliance. The solution supports hospitals and research organizations in optimizing patient care, resource allocation, and operational decisions. Founded in 2016 and based in San Mateo, California, Carta Healthcare focuses on turning disparate clinical data into actionable insights to improve care delivery.

SeQure DX is a biotechnology company specializing in genomics diagnostics for CRISPR-based gene editing therapies. It develops technologies that identify potential off-target sites prior to therapy initiation, ensuring comprehensive confirmation of actual edits. This enables safer and more effective gene editing therapeutics development, benefiting both researchers and patients.

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Walden Biosciences, Inc. is a biotechnology company dedicated to developing innovative treatments for individuals suffering from kidney diseases, including chronic kidney disease and acute kidney injury. Founded in 2013 and based in Cambridge, Massachusetts, the company focuses on targeting specific biological mechanisms related to renal health. It specializes in therapies that address suPAR, an inflammatory biomarker linked to kidney function, and Dynamin, an enzyme crucial for maintaining podocyte integrity. By applying a systems-based approach, Walden Biosciences aims to transform the therapeutic landscape for kidney disease, offering targeted treatment options that address both rare and prevalent conditions affecting kidney health.

ZielBio is an early-stage biotechnology company based in Charlottesville, Virginia. It identifies novel high-value disease targets and develops therapeutic interventions using its proprietary Zielfind platform, which combines functional high throughput screening with large content data analytics. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody targeting cell surface plectin for cancer treatment.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

Founded in 2016, Pykus Therapeutics develops a dissolvable intraocular surgical device designed to enhance retinal surgery by reducing patient discomfort. The company's core innovation is a polymer-based hydrogel that replaces the use of intraocular gas during such procedures, eliminating the need for patients to maintain face-down positioning and facilitating quicker recovery.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Massachusetts Eye and Ear is a hospital in Boston that specializes in research, education, and treatment of eye and ear conditions.

Health Catalyst is a technology company that specializes in data and analytics solutions for healthcare organizations. The company offers a platform that organizes, normalizes, and links health-related data from various systems, making it accessible and searchable for all users, including those without technical expertise. Health Catalyst operates through two main segments: the Technology segment, which generates the majority of its revenue through cloud-based subscriptions, time-based licenses, and maintenance fees for its data platforms and analytics applications; and the Professional Services segment, which provides a range of services including analytics, implementation, strategic advisory, and outsourcing to help clients optimize their use of the technology. By integrating and analyzing healthcare data, Health Catalyst aims to enhance decision-making and improve outcomes in the healthcare sector.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Provasculon is a biotechnology company founded to leverage a significant discovery made by Dr. Richard Lee and Dr. Vincent Segers at Brigham and Women's Hospital. The company focuses on the development of novel therapeutic proteins, particularly those related to the growth factor Stromal Cell-Derived Factor-1 (SDF-1). Provasculon's lead product is designed to aid in the healing of organs affected by ischemia, specifically targeting heart tissue that has suffered severe ischemic damage. This therapeutic approach aims to restore normal cardiac function, representing a potential advancement in the treatment of ischemic conditions.

Freedom2 is a biotechnology company founded nearly a decade ago with a mission to revolutionize tattoo removal. The company specializes in developing permanent tattoo ink removers using its proprietary Particle Encapsulation and Enhancement (P2E) Platform. This platform employs microscopic bioabsorbable pigments encapsulated in biocompatible polymers, forming microencapsulated colored beads that facilitate safe and easy future removal via a single standard laser treatment. Freedom2 aims to provide customers with a more affordable and less painful tattoo removal solution compared to traditional methods.

GlobeImmune, Inc. is a biopharmaceutical company based in Louisville, Colorado, specializing in the development of therapeutic products for cancer and infectious diseases utilizing its proprietary Tarmogen platform. Founded in 1995 as Ceres Pharmaceuticals, the company focuses on creating targeted molecular immunotherapies. Its product pipeline includes GS-4774, currently in Phase 2 trials for chronic hepatitis B infection, and GI-6301, aimed at cancers expressing the brachyury protein. Additionally, GlobeImmune is advancing GI-6207 for medullary thyroid cancer and GI-4000 for resected pancreatic cancer, with multiple Phase 2 clinical trials for various other cancers, including non-small cell lung cancer and colorectal cancer. The company is also developing several candidates targeting infectious diseases, including GI-19000 for tuberculosis, GI-2010 for HIV, and GI-18000 for hepatitis D, which are in preclinical stages. GlobeImmune has established strategic collaborations with notable organizations, enhancing its research and development efforts.

Radianse provides intelligent real-time tracking and situational awareness solutions for businesses. Its software automatically collects and processes live data on assets, recording history and making it accessible via a web-enabled interface. The company aims to deliver accessible, affordable, customized solutions that integrate data sources into real-time actionable intelligence, helping customers manage resources, control costs, increase revenue opportunities, and improve operational efficiency. Radianse has developed algorithms and methodologies to deliver reliable products with high accuracy and performance, protected by multiple patents. Originating from RFID-based monitoring, it now serves clients across industries, including corrections, eldercare, healthcare, and fitness sectors, applying real-time location systems, asset management, IoT, and intelligent enterprise services to optimize processes and throughput.

Carta Healthcare provides a software-as-a-service platform that maps the patient journey through hospitals by integrating data from existing information systems. The platform identifies potential bottlenecks weeks in advance and issues alerts about bed shortages and cancellations. It enables hospitals to personalize care by analyzing past patient journeys and using machine learning to predict what the current patient will need and what to expect during treatment. Its clinical data abstraction capabilities automate extraction and processing to improve efficiency, accuracy, and compliance. The solution supports hospitals and research organizations in optimizing patient care, resource allocation, and operational decisions. Founded in 2016 and based in San Mateo, California, Carta Healthcare focuses on turning disparate clinical data into actionable insights to improve care delivery.